Eton Pharmaceuticals, Inc. ETON
We take great care to ensure that the data presented and summarized in this overview for Eton Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETON
View all-
Opaleye Management Inc. Boston, MA2.78MShares$34.6 Million3.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.03MShares$12.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT999KShares$12.4 Million0.36% of portfolio
-
Westside Investment Management, Inc.619KShares$7.71 Million0.79% of portfolio
-
Acuitas Investments, LLC580KShares$7.23 Million1.66% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA566KShares$7.05 Million0.15% of portfolio
-
Paradigm Capital Management Inc300KShares$3.74 Million0.08% of portfolio
-
Black Rock Inc. New York, NY282KShares$3.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA273KShares$3.4 Million0.0% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT260KShares$3.24 Million0.22% of portfolio
Latest Institutional Activity in ETON
Top Purchases
Top Sells
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Insider Transactions at ETON
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 23
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.36%
|
$70,000
$7.98 P/Share
|
Oct 08
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
33,970
+2.84%
|
$237,790
$7.03 P/Share
|
Oct 07
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,248
+0.97%
|
$78,736
$7.22 P/Share
|
Oct 04
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,852
+1.45%
|
$101,112
$6.77 P/Share
|
Sep 11
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+3.94%
|
$200,000
$4.75 P/Share
|
Sep 10
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
57,500
+5.76%
|
$230,000
$4.65 P/Share
|
Sep 22
2022
|
Sean Brynjelsen President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.95%
|
$20,000
$2.1 P/Share
|
Nov 17
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,000
-1.04%
|
$100,000
$4.67 P/Share
|
Nov 16
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,438
-0.78%
|
$49,752
$4.86 P/Share
|
Nov 15
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000
-0.34%
|
$12,000
$4.8 P/Share
|
Nov 08
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
52,661
-2.51%
|
$315,966
$6.1 P/Share
|
Nov 05
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
167,701
-7.34%
|
$1,006,206
$6.3 P/Share
|
Nov 04
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
85,700
-3.48%
|
$514,200
$6.44 P/Share
|
Nov 03
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
116,500
-4.96%
|
$699,000
$6.53 P/Share
|
Oct 12
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,307
-3.4%
|
$436,535
$5.06 P/Share
|
Oct 11
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,101
-1.25%
|
$170,505
$5.01 P/Share
|
Oct 08
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
43,692
-1.84%
|
$218,460
$5.0 P/Share
|
Aug 20
2021
|
Sean Brynjelsen President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.96%
|
$40,000
$4.32 P/Share
|
Aug 20
2021
|
William Wilson Troutman CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
5,000
+17.84%
|
$20,000
$4.43 P/Share
|
Aug 06
2021
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
345,000
-10.68%
|
$1,725,000
$5.84 P/Share
|
Last 12 Months Summary
Open market or private purchase | 180K shares |
---|